SCHEMBL25520203

SCHEMBL25520203

CO[C@H]1C[C@@H](Nc2ncc3c(-c4ccc5nccnc5c4)c[nH]c3n2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.42
▸ CLK2 P49760 1/20 0.42
▸ CLK3 P49761 1/20 0.42
▸ RET P07949 1/20 0.41
▸ BRD4 O60885 2/20 0.39
▸ LATS1 O95835 1/20 0.37
▸ LATS2 Q9NRM7 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ PIM3 Q86V86 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.36
▸ DYRK1B Q9Y463 1/20 0.36
▸ KIT P10721 8/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ CCNK O75909 2/20 0.34
▸ CDK7 P50613 2/20 0.34
▸ CCNH P51946 2/20 0.34
▸ MNAT1 P51948 2/20 0.34
▸ CDK12 Q9NYV4 2/20 0.34
▸ MAP3K11 Q16584 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30347441 1.00 DYRK1A (0.42) DYRK1ACLK2CLK3RETBRD4
SCHEMBL30405737 0.91 RET (0.51) DYRK1ACLK2CLK3RETBRD4
SCHEMBL25519918 0.91 RET (0.51) DYRK1ACLK2CLK3RETBRD4
SCHEMBL25265918 0.89 DYRK1A (0.53) DYRK1ACLK2CLK3RETBRD4
SCHEMBL30406403 0.89 DYRK1A (0.53) DYRK1ACLK2CLK3RETBRD4
SCHEMBL25199109 0.89 DYRK1A (0.53) DYRK1ACLK2CLK3RETBRD4
SCHEMBL25520204 0.85 TDO2 (0.50) DYRK1ACLK2CLK3RETBRD4
SCHEMBL30407183 0.85 TDO2 (0.50) DYRK1ACLK2CLK3RETBRD4
SCHEMBL30406681 0.85 RET (0.44) DYRK1ACLK2CLK3RETBRD4
SCHEMBL25204277 0.84 ROCK2 (0.37) DYRK1ACLK2CLK3RETBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback